Please assess the completion status of the following clinical trial:

Trial Title: Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of chronic lymphocytic leukemia (CLL)~  * Stage 0, I, or II disease~ * Previously untreated disease~ * Splenomegaly, hepatomegaly, or lymphadenopathy are not required for the diagnosis of CLL~ * Absolute lymphocyte count \> 10,000/mm\^3~ * Lymphocytosis must consist of small to moderate size lymphocytes, with ≤ 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically~ * Phenotypically characterized B-CLL defined by all of the following criteria:~    * A population of leukemic cells that co-expresses the B-cell antigen CD23 as well as CD5 in the absence of other T-cell markers (CD3, CD2, etc.)~   * Dim surface immunoglobulin expression~   * Exclusively κ or λ light chains~ * Mantle cell lymphoma must be excluded by demonstrating the absence of the t(11:14) by FISH testing~* Patients who require chemotherapy for treatment of CLL, based on any of the following criteria, are excluded:~  * CLL-related symptoms requiring treatment, including any of the following:~    * Unintentional weight loss ≥ 10% body weight within the previous 6 months~   * Extreme fatigue~   * Fevers \> 100.5°F for 2 weeks without evidence of infection~   * Night sweats without evidence of infection~ * Evidence of progressive marrow failure due to CLL involvement of bone marrow as manifested by the development of worsening anemia (hemoglobin \< 11 g/dl) and/or thrombocytopenia (platelet count \< 100,000/mm\^3)~    * Thrombocytopenia due to immune phenomena (ITP) is permitted as long as platelet count is ≥ 100,000/mm\^3and the patient is not on active pharmacologic therapy~ * Massive (i.e. \> 6 cm below left costal margin) or progressive splenomegaly~ * Massive nodes or clusters (i.e., \> 10 cm in longest diameter) or progressive adenopathy~ * Progressive lymphocytosis with an increase of \> 50% over 2 month period, or an anticipated lymphocyte doubling time of \< 6 months~PATIENT CHARACTERISTICS:~* Platelet count ≥ 100,000/µL~* ANC ≥ 1500/µL~* Hemoglobin ≥ 11 g/dL~* Total or direct bilirubin ≤ 1.5 x upper limit of normal (ULN)~* AST (SGOT) and ALT (SGPT) ≤ 2 x ULN~* Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 40 mL/min~* May have a history of autoimmune hemolytic anemia (AIHA) and positive Coombs test provided there has not been active hemolysis requiring transfusion or steroid treatment ≤ 10 weeks prior to registration~* ECOG performance status 0, 1, or 2~* Life expectancy of ≥ 6 months~* No uncontrolled infection~* No myocardial infarction within the past 6 weeks~* No New York Heart Association class III or IV congestive heart failure~* Not pregnant or nursing~* Negative pregnancy test~* Must employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], or abstinence, etc.) prior to study entry and for the duration of study participation~* No other severe medical or psychiatric illness~* No active hemolysis requiring transfusion or other pharmacologic therapy~PRIOR CONCURRENT THERAPY:~* At least 8 weeks since prior and no other concurrent over the counter green tea or green tea extract~* No prior daily use of over the counter green tea products for medicinal purposes for \> 4 weeks (phase II only)~* No other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-FDA-approved indication and in the context of a research investigation)~* No concurrent combination anti-retroviral therapy for HIV positive patients~* No concurrent oral steroid preparations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- polyphenon E (Type: EXPERIMENTAL): Designed to assess toxicity, treatment response, and pertinent laboratory measurements in patients with previously untreated, asymptomatic, Rai Stage 0-II CLL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete